MedTech Dive · Aug 4, 2026
DeepHealth gets FDA nod for AI tool that reads ultrasounds, creates reports
DeepHealth’s tool automates lesion detection, characterization and reporting from breast ultrasound scans.
Medical Technology · page 2
Devices, digital health, and the technology changing how care is delivered.
MedTech Dive · Aug 4, 2026
Danaher promotes Julie Sawyer Montgomery to CEO
The executive has led Danaher’s diagnostics business, where she helped triple operating profit during her tenure and oversaw the recent acquisition of Masimo.
MedCity News · Aug 4, 2026
Health Tech Promised Simplicity — Why Does It Feel Like More Work?
The future of health care innovation is technology that carries more of the load, so people don’t have to. The post Health Tech Promised Simplicity — Why Does It Feel Like More Work? appeared first on MedCity News .
MedCity News · Aug 4, 2026
From Blind Spots to Better Outcomes: How SNF Data Transparency Strengthens LTSS
[Sponsored] What if health plans could identify member decline before an avoidable hospitalization occurs? Real-time clinical visibility into long-stay SNF members uncovers risk earlier and drives better outcomes. The post From Blind Spots to Better Outcomes: How SNF Data Transparency Strengthens LTSS appeared first on MedCity News .
MedCity News · Aug 4, 2026
The Trust Gap in Digital Health and AI Starts With Design — Here’s How to Close It
The gap between what technology can do and how much patients trust it won’t close on its own. Here are some design decisions that build trust — and some that quietly destroy it. The post The Trust Gap in Digital Health and AI Starts With Design — Here’s How to Close It appeared first on MedCity News .
Fierce Biotech · Aug 4, 2026
Amgen drops early-stage obesity drug, upping pressure on MariTide
Amgen has ended development of its early-stage obesity drug AMG 513, foisting its hopes for a slice of the massive weight loss market onto the shoulders of phase 3 candidate MariTide.
Fierce Biotech · Aug 4, 2026
Smith & Nephew cuts 2026 outlook as US knee implant sales slide
Smith & Nephew has lowered its 2026 sales outlook after weakness in U.S. orthopedics and wound care outweighed stronger growth in sports medicine.
Fierce Biotech · Aug 4, 2026
Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout
Pfizer has axed two clinical-stage obesity programs, dropping a GLP-1 receptor agonist from the Metsera buyout and a GIPR antagonist as part of its quarterly pipeline cleanout.
Fierce Biotech · Aug 4, 2026
KKR inks $5.7B deal to take medtech manufacturing giant Integer private
Private equity giant KKR is expanding its healthcare portfolio with a deal to take medtech manufacturing giant Integer private for approximately $5.7 billion.
Fierce Biotech · Aug 4, 2026
Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx
Latigo Biotherapeutics has fleshed out its plans for an IPO to finance the development of its clinical-stage pipeline of non-opioid pain management drugs.
Fierce Biotech · Aug 4, 2026
Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact
Pathos AI has agreed to pay $125 million for a bispecific antibody-drug conjugate from China’s Alphamab Oncology, while adding a Big Pharma partner in the form of AstraZeneca.
MedCity News · Aug 3, 2026
HHS Is Reviving Its 340B Rebate Push — And Providers Are None Too Pleased
HHS is reviving a rebate program for 340B drug discounts after the previous pilot was blocked in court earlier this year. Providers say the change will burden already cash-strapped providers with new administrative and financial costs. The post HHS Is Reviving Its 340B Rebate Push — And Providers Are None Too Pleased appeared first on MedCity News .
MedTech Dive · Aug 3, 2026
KKR to take Integer private for $5.7B
Integer expects to gain flexibility and capital to invest in its contract development and manufacturing business under KKR.
MedTech Dive · Aug 3, 2026
Siemens Healthineers names new head of the Americas
The company disclosed the appointment of João Seabra the day before cutting its full-year sales outlook in response to continued challenges at its diagnostics division.
Fierce Biotech · Aug 3, 2026
Curium strikes up to $8B deal for radiopharma rival Lantheus
Months after reports first linked Curium to a potential Lantheus takeover, the radiopharma players have made it official with a deal worth up to $8 billion.
MedCity News · Aug 3, 2026
From Ethics to Trust: Strategic Guardrails for Safe, Secure, Effective AI in Healthcare
Ethical AI and trustworthy AI frameworks should be table stakes for healthcare and life sciences organizations seeking to innovate with AI. The post From Ethics to Trust: Strategic Guardrails for Safe, Secure, Effective AI in Healthcare appeared first on MedCity News .
MedCity News · Aug 3, 2026
Beyond Adoption: The Habits Shaping Digital Health
The products that succeed over time are usually the ones that make life easier, fit naturally into existing routines and continue delivering value long after the novelty wears off. The post Beyond Adoption: The Habits Shaping Digital Health appeared first on MedCity News .
MedTech Dive · Aug 3, 2026
Henry Schein removes 3 longtime execs in leadership shakeup
The reorganization comes months after Fred Lowery was named CEO and the company deepened its relationship with private equity firm KKR.
Fierce Biotech · Aug 3, 2026
Fiercest Women in Life Sciences 2026: Nominations open now
Who should be a 2026 Fiercest Woman in Life Sciences? Nominations are open for women making an impact across pharma, biotech, medtech and beyond. The deadline is Sept. 18.
Fierce Biotech · Aug 3, 2026
BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
BlossomHill Therapeutics plans to raise $111.7 million to fund the clinical journey of its potential challenger to Tagrisso.
Fierce Biotech · Aug 3, 2026
After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
One of the most closely watched vacancies in biopharma has now been filled, with Sobi CEO Guido Oelkers, Ph.D., moving across to take up the top job at mRNA pioneer BioNTech.
Fierce Biotech · Aug 3, 2026
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, cost numerous jobs, all while damaging the broader biopharma ecosystem and hurting patients, Angus Liu argues in an editorial.
MedCity News · Aug 2, 2026
Apnimed’s IPO Bags $192M for What Could Become the First Oral Sleep Apnea Drug
Apnimed will apply the IPO proceeds toward the regulatory process and launch plans of Oxnimbi, a once-nightly pill developed for obstructive sleep apnea. This drug is under FDA review with a February 2027 target date for a regulatory decision. The post Apnimed’s IPO Bags $192M for What Could Become the First Oral Sleep Apnea Drug appeared first on MedCity News .
MedCity News · Aug 2, 2026
4 Notable Health Tech Funding Announcements in July
Health tech companies made several major funding announcements in July. Here is a list of some of the biggest funding rounds. The post 4 Notable Health Tech Funding Announcements in July appeared first on MedCity News .